Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Gross Margin (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Gross Margin for 6 consecutive years, with 69.65% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin rose 43.0% to 69.65% in Q4 2025 year-over-year; TTM through Dec 2025 was 69.74%, a 610.0% increase, with the full-year FY2025 number at 69.74%, up 610.0% from a year prior.
  • Gross Margin was 69.65% for Q4 2025 at GeneDx Holdings, down from 72.4% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 161.22% in Q2 2021 to a low of 81.83% in Q2 2022.
  • A 5-year average of 37.7% and a median of 50.47% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: plummeted -24305bps in 2022, then skyrocketed 12034bps in 2023.
  • GeneDx Holdings' Gross Margin stood at 4.85% in 2021, then tumbled by -448bps to 26.61% in 2022, then soared by 301bps to 53.56% in 2023, then increased by 29bps to 69.22% in 2024, then increased by 1bps to 69.65% in 2025.
  • Per Business Quant, the three most recent readings for WGS's Gross Margin are 69.65% (Q4 2025), 72.4% (Q3 2025), and 69.04% (Q2 2025).